Limiting 'Futile' Treatment for Terminal Patients Saves Few Dollars

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 1
Volume 4
Issue 1

HANOVER, NH--Results of a multicenter study debunk the view that limiting 'futile' life-sustaining treatments for terminally ill patients will produce significant health-care savings. "Cutting off care through strict 'futility guidelines' will save few dollars and not much suffering," said Joanne Lynn, MD, of Dartmouth-Hitchcock Medical Center.

HANOVER, NH--Results of a multicenter study debunk the view thatlimiting 'futile' life-sustaining treatments for terminally illpatients will produce significant health-care savings. "Cuttingoff care through strict 'futility guidelines' will save few dollarsand not much suffering," said Joanne Lynn, MD, of Dartmouth-HitchcockMedical Center.

In this study of more than 4,000 patients, all of whom were hospitalizedand in an advanced stage of a serious condition, 115 had beengiven less than a 1% chance of surviving for 2 months. The totalhospital bill for these sickest patients was $8.8 million, andprecluding the life-sustaining treatments they received wouldhave saved only $1.2 million (JAGS 42:1202-1207, 1994).

Of these sickest patients, almost 86% died within 5 days of prognosis,and all but one died within 6 months. "For the vast majorityof the sickest patients, death occurs within 5 days of the onsetof serious illness," she said. "For those not quiteso sick, I don't think society is ready to demand that treatmentbe stopped when we still can't predict precisely who will dieand when they will die."

Eliminating futile care for 12 patients would have resulted innearly 75% of the savings in hospital days. But some of thesepatients had a very strong desire to try all possible interventionsto save their lives. Some of them said they definitely wantedresuscitation, based on their religious beliefs. Others were youngpeople who had complications after organ transplant. "Stoppingtreatment quickly is hard to justify in these cases," Dr.Lynn said.

She suggested that a better alternative to futility guidelineswould be to "ensure that decision-making is informed by thepatient's preferences and likely outcomes of care." Healthprofessionals might also provide more support to dying patientsand their families, so that they can more readily stop futiletreatments.

Related Videos
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Exercise and healthy lifestyles can lower the risk of cancer or the symptoms of cancer treatment despite having genetic dispositions, said Neil M. Iyengar, MD.
Cell therapy and vaccine approaches are among the several potential options for targeting KRAS in patients with KRAS G12C–mutated non–small cell lung cancer, says Sandip P. Patel, MD.
Marwan G. Fakih, MD, and Atif Hussein, MD, MMM, FACP, experts on colorectal cancer
A panel of 4 experts on multiple myeloma seated at a long table
A panel of 4 experts on multiple myeloma seated at a long table
Experts on MM
Related Content